Greenwich LifeSciences screens over 1,000 patients in Flamingo-01 cancer trial

Greenwich LifeSciences (GLSI) provided an update on FLAMINGO-01, its Phase III clinical trial which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. The company has achieved a milestone by screening over 1,000 patients in Flamingo-01, continuing its screening rate of approximately 150 patients per quarter or the equivalent of 600 patients per year in 140 active sites. The company is considering a strategy to continue enrolling in both the HLA-A*02 and non-HLA-A*02 arms until interim analyses are conducted and the appropriate size of each arm can be further assessed.